EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Beyond the label ‘high‐grade’: histological heterogeneity as a prognostic marker in Ta non‐muscle‐invasive bladder cancer

Francis Simard iD, Marie-Maxime Lacombe iD, David Simonyan iD, Charles-Antoine Garneau iD, Edouard Cazes iD, Coralie Deschênes iD, Sophie Morin iD, Paul Toren iD, Alain Bergeron iD, Alexandre Zlotta, Wassim Kassouf iD, Chantal Atallah iD und 1 weitere

BJU International · 02.11.2026

DOI: 10.1111/bju.70522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 02.11.2026. Verfasst von Francis Simard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, CHU de Québec-Université Laval, Québec City, Quebec, Canada. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CHU de Québec-Université Laval Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate whether the proportion of a high‐grade (HG) component within primary non‐muscle‐invasive bladder cancer (NMIBC) influences recurrence and progression outcomes beyond the current World Health Organization (WHO) recommended threshold of ≥5% to designate a tumour as HG. Patients and Methods We conducted a retrospective cohort study of patients diagnosed with primary pathological T stage (pT)a HG NMIBC. All cases underwent centralised genitourinary pathological re‐review to quantify the percentage of the HG component. Patients were stratified using pre‐defined HG cut‐offs (5%, 10%, 25%, 50%, and 100%). Recurrence‐free survival and progression‐free survival (PFS) were assessed using Kaplan–Meier analyses and multivariable Cox proportional hazards models, adjusting for established clinicopathological factors. Subgroup analyses were performed according to intravesical Bacillus Calmette–Guérin (BCG) treatment.

Results

From 466 patients identified in our database, 362 underwent centralised pathologic re‐review, and a total of 321 patients with confirmed pTa urothelial carcinoma were included in the study. The median follow‐up was 61.3 months. The overall incidence of recurrence and progression, defined as progression to pathological stage ≥T1, was 35.5% and 9.4%, respectively. Increasing HG proportion was not significantly associated with recurrence after multivariable adjustment, whereas age and tumour multiplicity independently predicted recurrence risk. In contrast, higher HG percentage thresholds (≥10%, ≥25%, ≥50%, and 100%) were associated with progressively worse PFS, most pronounced in exploratory subgroups without BCG. The 5% threshold did not significantly discriminate outcomes.

Conclusion

The overall burden of HG differentiation seems to provide better prognostic significance than the mere presence of mixed histology in HG pTa tumours. Using higher HG percentage thresholds might improve the identification of patients at risk of progression and enhance risk stratification beyond existing WHO criteria. Prospective studies are needed to confirm if including HG percentage in clinical decision‐making can lead to better personalised treatment for NMIBC.

Schlagwörter

Stichwörter der Autor:innen

grade heterogeneitynon‐muscle‐invasive bladder cancerpTa tumourspathologysurvival

Autor:innen und Institutionen

  • Department of Urology, CHU de Québec-Université Laval, Québec City, Quebec, Canada.
  • Department of Pathology, CHU de Québec-Université Laval, Québec City, Quebec, Canada.
  • CHU de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • Department of Surgery, University Laval, Québec City, Quebec, Canada.
  • Department of Surgery (Urology), Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Department of Surgery (Urology), McGill University Health Centre, McGill University, Montréal, Quebec, Canada.

ORCID-Profile: Francis Simard, Marie-Maxime Lacombe, David Simonyan, Charles-Antoine Garneau, Edouard Cazes, Coralie Deschênes, Sophie Morin, Paul Toren, Alain Bergeron, Wassim Kassouf, Chantal Atallah, Michele Lodde

Förderung

  • CHU de Québec-Université Laval Research Center

Zitieren

APA

Simard, F., Lacombe, M. M., Simonyan, D., Garneau, C. A., Cazes, E., Deschênes, C., Morin, S., Toren, P., Bergeron, A., Zlotta, A., Kassouf, W., Atallah, C., & Lodde, M. (2026). Beyond the label ‘high‐grade’: histological heterogeneity as a prognostic marker in Ta non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.70522

Vancouver

Simard F, Lacombe MM, Simonyan D, Garneau CA, Cazes E, Deschênes C, et al. Beyond the label ‘high‐grade’: histological heterogeneity as a prognostic marker in Ta non‐muscle‐invasive bladder cancer. BJU International. 2026. doi:10.1111/bju.70522

BibTeX
@article{Simard2026,
  author = {Simard, Francis and Lacombe, Marie-Maxime and Simonyan, David and Garneau, Charles-Antoine and Cazes, Edouard and Deschênes, Coralie and Morin, Sophie and Toren, Paul and Bergeron, Alain and Zlotta, Alexandre and Kassouf, Wassim and Atallah, Chantal and Lodde, Michele},
  title = {Beyond the label ‘high‐grade’: histological heterogeneity as a prognostic marker in Ta non‐muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.70522}
}
Kostenlos starten →